Tracer library / [177Lu]Lu-DOTA-A1K2

[177Lu]Lu-DOTA-A1K2

Also written as [177Lu]Lu-DOTA-A1K2

Radionuclide: Lu-177
Modality: —
Production route: —
Stage: Preclinical
Syntheses indexed: 1

What it is

Compound class: Anti-mesothelin single-domain antibody (sdAb/nanobody) conjugated with DOTA
Target / mechanism: Mesothelin (MSLN), a 40 kDa glycoprotein PMID 41454065
Clinical application: Mesothelin-positive tumors, including triple-negative breast cancer (TNBC) PMID 41454065
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	98.0 ± 1.7%	DOTA-A1K2	41454065 2026 Eur J Nucl Med Mol Imaging Radiolabeling with ¹⁷⁷Lu (177Lu3+ in aqueous 0.04 M HCl solution; ITM Radiopharma, Germany) was performed by mixing 100 µg of DOTA-A1K2-conjugated sdAb (7–8 nmol) with 150–200 µL of 0.1 M ammonium acetate buffer.

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-A1K2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 40293556, 41454065. Stage set/updated at stage 39 from PMID 41454065: 'In vivo, efficacy was evaluated over 9 weeks after a single intravenous injection of 2, 5, 10, or 20 MBq.'.